Arcus Biosciences Inc (RCUS) Stock AnalysisRCUSArcus Biosciences Inc

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arcus Biosciences (RCUS) is a good buy right now, trading at $18.54 with a significant upside potential. The stock has a low Relative Strength Index (RSI) of 22.588, indicating it is oversold and may rebound. Additionally, hedge funds have increased their buying activity by 186.42% over the last quarter, suggesting strong institutional interest. The main risk is the company's negative earnings, with an EPS estimate of -0.92 for the next earnings report on October 27, 2026.

3 analysts cover RCUS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 27.44.